- Previous Close
27.12 - Open
26.73 - Bid 27.35 x --
- Ask 27.37 x --
- Day's Range
26.73 - 27.51 - 52 Week Range
23.61 - 37.08 - Volume
3,841,660 - Avg. Volume
7,070,410 - Market Cap (intraday)
6.414B - Beta (5Y Monthly) 0.19
- PE Ratio (TTM)
13.10 - EPS (TTM)
2.09 - Earnings Date --
- Forward Dividend & Yield 2.50 (9.22%)
- Ex-Dividend Date Sep 27, 2024
- 1y Target Est
--
Shandong Wit Dyne Health Co.,Ltd. engages in the pharmaceutical business in China. Its medical products include azithromycin granules, licorice zinc granules, compound calcium carbonate, vitamin AD drops, epalrestat tablets, valsartan hydrochlorothiazide gel, roxithromycin, rosiglitazone tartrate tablets, and glimepiride tablets. The company also provides dextran iron granules, oral rehydration salt powder, montmorillonite powder, zithromycin granules, rifaximin dry suspension, and dithiothreitol succinate capsules. In addition, it offers information products, such as DLP splicing display units, LCD splicing display units, image splicing processors, communication products, and industrial automation control products; and crystal products. Further, the company is involved in the provision of education services. Shandong Wit Dyne Health Co.,Ltd. was founded in 1993 and is based in Jinan, China.
www.sd-wit.com1,763
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 000915.SZ
View MorePerformance Overview: 000915.SZ
Trailing total returns as of 1/16/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 000915.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 000915.SZ
View MoreValuation Measures
Market Cap
6.36B
Enterprise Value
3.30B
Trailing P/E
12.98
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.97
Price/Book (mrq)
2.30
Enterprise Value/Revenue
1.54
Enterprise Value/EBITDA
3.03
Financial Highlights
Profitability and Income Statement
Profit Margin
22.86%
Return on Assets (ttm)
13.43%
Return on Equity (ttm)
22.21%
Revenue (ttm)
2.14B
Net Income Avi to Common (ttm)
489.89M
Diluted EPS (ttm)
2.09
Balance Sheet and Cash Flow
Total Cash (mrq)
2.72B
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
468.31M